New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline

Maura Corsetti, Peter Whorwell

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science